57.56 1.06 (1.88%)

New 52W Low today

6.8M XNAS Volume

XNAS 17 Apr, 2025 5:30 PM (EDT)

Board Meeting
The next board meeting for Hologic, Inc. is on 01 May 2025 for the purpose of Hologic Inc Second Quarter Earnings Conference Call for 2025 See details

Hologic, Inc. Key Metrics

Select
All financials are in USD Million and price data in USD
VIEW MORE
High Financial Strength
66.7 / 100
Affordable Valuation
59.2 / 100
Technically Bearish
28.4 / 100
Value Stock, Under Radar These stocks are strong in quality and valuation, but score weak in technical aspects. Hence, it is better to wait for the stock to change their momentum. View Similar Embed DVM

Hologic, Inc. Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Sep '22Sep '23Sep '24Sep '25Sep '263500400045005000Actual RevenueAvg. Estimate
Hit

Hologic, Inc.'s Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

Current EPS
3.3
Avg. Estimate
3.5
Low Estimate
3.2
High Estimate
3.6
Current EPS
Avg. Estimate
Hit

EPS is expected to grow by 4.5% in FY25

Consensus Recommendation

21 ANALYST Recommendations
HOLD

Created with Highcharts 7.2.214Hold4Buy3Strong Buy

The consensus recommendation from 21 analysts for Hologic, Inc. is HOLD

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Hologic, Inc. Stock Analysis

Hologic, Inc. stock analysis with key metrics, changes, and trends.

Hologic, Inc. MetricVALUECHANGE %TRENDANALYSIS
Annual Net Profit$789.5 M73.14%positive

Annual Net Profit rose 73.14% in the last year to $789.5 M. Its sector's average net profit growth for the last fiscal year was 4.36%.

Price to Earning Ratio17.46-positive

Price to Earning Ratio is 17.46, lower than its sector PE ratio of 29.09.

Stock Price$57.56-23.64%negative

Stock Price fell 23.64% and underperformed its sector by 29.07% in the past year.

Quarterly Revenue$1,021.8 M0.86%positive

Quarterly Revenue rose 0.86% YoY to $1,021.8 M. Its sector's average revenue growth YoY for the quarter was 8.5%.

Quarterly Net profit$201 M18.46%negative

Quarterly Net profit fell 18.46% YoY to $201 M. Its sector's average net profit growth YoY for the quarter was 32.89%.

Debt to Equity Ratio0.52-positive

Debt to Equity Ratio of 0.52 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)15.56 %15.56%neutral

Return on Equity(ROE) for the last financial year was 15.56%, in the normal range of 10% to 20%.

Mutual Fund Holding84.56 %-1.8%negative

Mutual Fund Holding decreased by 1.8% in the last quarter to 84.56.

Promoter Share Holding0.75 %0.01%positive

Promoter Share Holding increased by 0.01% in the most recent quarter to 0.75%.

Interest Coverage Ratio8.09-positive

Interest Coverage Ratio is 8.09, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

Institutional Holding100.78 %0.35%positive

Institutional Holding increased by 0.35% in the last quarter to 100.78.

VIEW LESS


Loading data..

Hologic, Inc. - Company Profile

What does Hologic, Inc. do?

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Hologic, Inc. Management structure

All Gross Remunerations are in USD
Mr. John M. Griffin
General Counsel
-
2025
Gross Remuneration
Year

Hologic, Inc. Board of directors

All Gross Remunerations are in USD
Dr. Martin D. Madaus,PhD
Director
-
2025
Gross Remuneration
Year
Mr. Scott T. Garrett
Independent Director
-
2025
Gross Remuneration
Year
Ms. Sally Wellinghoff Crawford
Independent Director
-
2025
Gross Remuneration
Year
Mr. Wayde D. McMillan
Director
-
2025
Gross Remuneration
Year

Hologic, Inc. FAQ

How is Hologic, Inc. today?
Hologic, Inc. today is trading in the green, and is up by 1.88% at 57.56.
Hologic, Inc. is currently trading up 1.88% on an intraday basis. In the past week the stock fell -0.50%. stock has been down -17.45% in the past quarter and fell -23.64% in the past year. You can view this in the overview section.